Searched for
GLAXOSMITHKLINE PHARMA EARNINGS
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- I-Sec upgrades GlaxoSmithKline Pharma to Add, lowers target price to Rs 2,250ICICI Securities has raised its rating on GlaxoSmithKline Pharmaceuticals to Add from Hold with a new target price of Rs 2250. GSK Pharma's...
- GlaxoSmithKline Pharma Q4 Results: Firm posts net loss at Rs 55 croreRevenue from operations rose to Rs 810 crore for the fourth quarter compared to Rs 744 crore in the year-ago period, GlaxoSmithKline Pharma...
- GSK Pharma Q1 net profit up 35% at Rs 113.54 croreStandalone total income of the company also rose to Rs 818.78 crore for the quarter.
- Market now: Nifty Pharma index up; Lupin, Divi's Lab top gainersBesides pharma, IT stocks were also gaining in trade.
- GSK Pharma profit up 6.53% at Rs 102.85 cr in Jan-Mar quarterGlaxoSmithKline Pharmaceuticals today reported 6.53 per cent increase in standalone net profit at Rs 102.85 crore for the Jan-March quarter.
- Dilip Shanghvi overtakes Mukesh Ambani as richest IndianShanghvi's networth today stood at $21.5 bn, following a sharp rally in share prices of his group companies, while that of Ambani was $20.4...
- GSK Pharma open offer begins today; stock hits 52-week highGSK Pharma continued to attract investor attention after its UK-based parent company GlaxoSmithKline’s voluntary open offer started today.
- $1 billion bet: GSK Pharma a short-term sell, long-term buy, say expertsThe stock is at rich valuations despite low sales and profit growth. The open offer by its parent firm is attractively priced, say experts.
- GlaxoSmithKline Q3 Net declines 33.73 per cent to Rs 100.95 crThe company had posted a standalone net profit of Rs 152.34 crore in the same period previous fiscal, GSK Pharma said in a filing with the ...
- GlaxoSmithKline Pharma PAT seen up 16% at Rs 171 crGlaxoSmithKline Pharmaceuticals Ltd is expected to post a net profit of Rs 171 crore for the June 2012 quarter, a 16 per cent YoY increase ...
- Oberoi Realty up on green nod for residential projectOberoi Realty has received environmental clearance for its proposed residential project in Mulund, a central suburb of Mumbai.
- Midcaps, small cap to give good returns; bullish on midcap pharma: Satish BetadpurET Now spoke to Satish Betadpur, CFA, Global Research Director, Independent International Investment Research PLC, on his view on pharma st...
- GlaxoSmithKline: Strong sales focus to help co do better than its peersGlaxoSmithKline (GSK) Pharma, the third-largest player in the domestic pharma market, started the year on a healthy note. Kiran Kabtta Somv...
- Nissan, Pfizer may exit Satyam; invite bids from other vendorsWhile TCs, Wipro & cognizant bid for $35 mn Nissan contract, cognizant is leading race for Pfizer's IT contract. Satyam's Development Centr...
- Nissan, Pfizer may exit Satyam; invite bids from other vendorsWhile TCs, Wipro & cognizant are bidding for $35 mn Nissan contract, cognizant is learnt to be leading race for Pfizer's IT contract. Satya...
- Pharma- the mantra in a negative marketWhile the Asian markets are reacting to the negative vibes of recession in the US, pharmaceutical companies seem to be favoured by investor...
- Religare maintains buy on GSK Pharma, Sujana TowersReligare Securities has maintained 'buy' on GlaxoSmithKline Pharma with a target price of Rs 1,192 based on 20 times CY09E earnings.
- Ranbaxy's pact with GSK gives it scope for drug devtRanbaxy Labs had earlier entered into an agreement with GlaxoSmithKline, under which the domestic pharma major was responsible for selectin...
Load More
